Immuneering (IMRX) Stock Forecast, Price Target & Predictions
IMRX Stock Forecast
Immuneering stock forecast is as follows: an average price target of $17.50 (represents a 775.00% upside from IMRX’s last price of $2.00) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
IMRX Price Target
The average price target for Immuneering (IMRX) is $17.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $41.00 to $3.00. This represents a potential 775.00% upside from IMRX's last price of $2.00.
IMRX Analyst Ratings
According to 4 Wall Street analysts, Immuneering's rating consensus is 'Buy'. The analyst rating breakdown for IMRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (75.00%), 0 'Hold' (0.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
Immuneering Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 02, 2024 | Graig Suvannavejh | Mizuho Securities | $8.00 | $2.75 | 190.91% | 300.00% |
| Mar 15, 2024 | Michael Yee | Jefferies | $3.00 | $1.91 | 57.07% | 50.00% |
| Sep 30, 2022 | Swapnil Malekar | Piper Sandler | $41.00 | $15.50 | 164.52% | 1950.00% |
| Jul 09, 2022 | Geulah Livshits | Loop Capital Markets | $18.00 | $7.28 | 147.25% | 800.00% |
The latest Immuneering stock forecast, released on Apr 02, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $8.00, which represents a 190.91% increase from the stock price at the time of the forecast ($2.75), and a 300.00% increase from IMRX last price ($2.00).
Immuneering Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $5.50 |
| Last Closing Price | $2.00 | $2.00 | $2.00 |
| Upside/Downside | -100.00% | -100.00% | 175.00% |
In the current month, the average price target of Immuneering stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immuneering's last price of $2.00. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 13, 2024 | Morgan Stanley | Underweight | Downgrade | |
| Apr 19, 2023 | Mizuho Securities | Buy | Upgrade | |
| Jul 25, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 09, 2022 | Chardan Capital | Buy | Initialise |
Immuneering's last stock rating was published by Morgan Stanley on Dec 13, 2024. The company Downgrade its IMRX rating from "null" to "Underweight".
Immuneering Financial Forecast
Immuneering Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $456.00 | $38.38K | $94.42K | $183.70K | $2.08B | $482.13K | $660.04K |
| Avg Forecast | - | - | - | - | - | - | - | $8.33K | $60.00K | $153.33K | $196.80K | $182.00K | $535.50K | $700.00K | $725.00K |
| High Forecast | - | - | - | - | - | - | - | $8.33K | $60.00K | $153.33K | $196.80K | $182.00K | $535.50K | $700.00K | $725.00K |
| Low Forecast | - | - | - | - | - | - | - | $8.33K | $60.00K | $153.33K | $196.80K | $182.00K | $535.50K | $700.00K | $725.00K |
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 0.01% | 0.25% | 0.48% | 1.01% | 3880.62% | 0.69% | 0.91% |
Immuneering's average Quarter revenue forecast for Mar 23 based on 1 analysts is $8.33K, with a low forecast of $8.33K, and a high forecast of $8.33K. IMRX's average Quarter revenue forecast represents a 1727.41% increase compared to the company's last Quarter revenue of $456.00 (Dec 22).
Immuneering EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-14.49M | $-13.98M | $-12.98M | $-11.44M | $-12.73M | $-14.68M | $-8.50M | $-7.95M |
| Avg Forecast | - | - | - | - | - | - | - | $-5.00K | $-36.00K | $-92.00K | $-118.08K | $-11.45M | $-321.30K | $-10.45M | $-435.00K |
| High Forecast | - | - | - | - | - | - | - | $-5.00K | $-36.00K | $-92.00K | $-118.08K | $-9.16M | $-321.30K | $-8.36M | $-435.00K |
| Low Forecast | - | - | - | - | - | - | - | $-5.00K | $-36.00K | $-92.00K | $-118.08K | $-13.74M | $-321.30K | $-12.54M | $-435.00K |
| Surprise % | - | - | - | - | - | - | - | 2898.50% | 388.27% | 141.13% | 96.91% | 1.11% | 45.69% | 0.81% | 18.27% |
undefined analysts predict IMRX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immuneering's previous annual EBITDA (undefined) of $NaN.
Immuneering Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $1.06B | $-12.51M | $-12.50M | $-11.41M | $-12.87M | $-14.37M | $-8.53M | $-7.99M |
| Avg Forecast | $-9.70M | $-10.30M | $-10.89M | $-11.79M | $-13.68M | $-16.47M | $-15.42M | $-16.15M | $-16.75M | $-14.23M | $-15.21M | $-11.75M | $-11.45M | $-10.49M | $-49.08M |
| High Forecast | $-9.70M | $-10.30M | $-10.89M | $-9.82M | $-8.73M | $-16.47M | $-15.42M | $-16.15M | $-16.75M | $-14.23M | $-15.21M | $-9.40M | $-11.45M | $-8.39M | $-49.08M |
| Low Forecast | $-9.70M | $-10.30M | $-10.89M | $-13.42M | $-18.04M | $-16.47M | $-15.42M | $-16.15M | $-16.75M | $-14.23M | $-15.21M | $-14.10M | $-11.45M | $-12.59M | $-49.08M |
| Surprise % | - | - | - | - | - | - | - | -65.74% | 0.75% | 0.88% | 0.75% | 1.10% | 1.26% | 0.81% | 0.16% |
Immuneering's average Quarter net income forecast for Jun 24 is $-15.42M, with a range of $-15.42M to $-15.42M. IMRX's average Quarter net income forecast represents a -101.45% decrease compared to the company's last Quarter net income of $1.06B (Mar 23).
Immuneering SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $4.46M | $4.11M | $3.84M | $3.70M | $3.95M | $3.79M | $2.60M | $1.34M |
| Avg Forecast | - | - | - | - | - | - | - | $94.95K | $683.67K | $1.75M | $2.24M | $2.07M | $6.10M | $7.98M | $8.26M |
| High Forecast | - | - | - | - | - | - | - | $94.95K | $683.67K | $1.75M | $2.24M | $2.07M | $6.10M | $7.98M | $8.26M |
| Low Forecast | - | - | - | - | - | - | - | $94.95K | $683.67K | $1.75M | $2.24M | $2.07M | $6.10M | $7.98M | $8.26M |
| Surprise % | - | - | - | - | - | - | - | 46.98% | 6.01% | 2.20% | 1.65% | 1.91% | 0.62% | 0.33% | 0.16% |
Immuneering's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to IMRX last annual SG&A of $4.46M (Mar 23).
Immuneering EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $40.16 | $-0.47 | $-0.47 | $-0.43 | $-0.49 | $-0.55 | $-0.47 | $-0.33 |
| Avg Forecast | $-0.33 | $-0.34 | $-0.36 | $-0.40 | $-0.46 | $-0.55 | $-0.52 | $-0.54 | $-0.56 | $-0.48 | $-0.51 | $-0.44 | $-0.39 | $-0.56 | $-1.66 |
| High Forecast | $-0.33 | $-0.34 | $-0.36 | $-0.33 | $-0.29 | $-0.55 | $-0.52 | $-0.54 | $-0.56 | $-0.48 | $-0.51 | $-0.44 | $-0.39 | $-0.56 | $-1.66 |
| Low Forecast | $-0.33 | $-0.34 | $-0.36 | $-0.45 | $-0.60 | $-0.55 | $-0.52 | $-0.54 | $-0.56 | $-0.48 | $-0.51 | $-0.44 | $-0.39 | $-0.56 | $-1.66 |
| Surprise % | - | - | - | - | - | - | - | -74.20% | 0.84% | 0.98% | 0.84% | 1.12% | 1.42% | 0.84% | 0.20% |
According to 0 Wall Street analysts, Immuneering's projected average Quarter EPS for Jun 24 is $-0.52, with a low estimate of $-0.52 and a high estimate of $-0.52. This represents a -101.29% decrease compared to IMRX previous annual EPS of $40.16 (Mar 23).
Immuneering Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IVA | Inventiva | $2.28 | $36.00 | 1478.95% | Buy |
| IMRX | Immuneering | $1.73 | $17.50 | 911.56% | Buy |
| GOSS | Gossamer Bio | $0.87 | $3.75 | 331.03% | Buy |
| PMVP | PMV Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| LRMR | Larimar Therapeutics | $4.32 | $17.00 | 293.52% | Buy |
| CMPX | Compass Therapeutics | $1.53 | $5.00 | 226.80% | Buy |
| CELC | Celcuity | $12.55 | $39.00 | 210.76% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| REPL | Replimune Group | $11.72 | $19.00 | 62.12% | Buy |
| ELVN | Enliven Therapeutics | $24.39 | $39.50 | 61.95% | Buy |
| NAMS | NewAmsterdam Pharma Company | $26.61 | $39.33 | 47.80% | Buy |
| CNTA | Centessa Pharmaceuticals | $17.60 | $23.25 | 32.10% | Buy |
| KRON | Kronos Bio | $0.96 | $1.00 | 4.17% | Buy |
| IKNA | Ikena Oncology | $1.62 | $1.33 | -17.90% | Buy |